Cyclopharm (ASX:CYC) shares experienced an 11.3% surge, elevating its market value to A$3.150 - a peak not witnessed since January 28, 2021.

The healthcare company, specializing in medical equipment and technology, announced that it has procured a coveted approval from the US Food and Drug Administration to initiate commercial sales of Technegas in America.

Technegas is a diagnostic tool used in the management of pulmonary embolism or, as it’s more colloquially known, lung artery blockage.

The company’s shares were traded 172,232 times, which is 5.4 times their average 30-day trade volume of 32,360.

An impressive performance given the company’s stock has more than doubled its value so far this year.

Cyclopharm (ASX:CYC) is a medical equipment and technology provider recognized for its revolutionary contribution in pulmonary care.